Request Demo

Last update 08 May 2025

Irritable Bowel Syndrome

Last update 08 May 2025

Basic Info

Synonyms

Adaptive colitis, BOWEL IRRITABLE, BOWEL IRRITABLE SYNDROME

+ [115]

Introduction

A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.

248

Drugs associated with Irritable Bowel Syndrome

Rimegepant Sulfate

Target

CGRP receptor

Mechanism

CALCRL antagonists

Active Org.

Catalent U.K. Swindon Zydis Ltd. [+8]

Originator Org.

Biohaven Ltd.

Active Indication

Acute migraine [+8]

Inactive Indication

Temporomandibular Joint Disorders [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date27 Feb 2020

Tenapanor Hydrochloride

Target

NHE3

Mechanism

NHE3 inhibitors

Active Org.

Ardelyx, Inc. [+3]

Originator Org.

Ardelyx, Inc.

Active Indication

Hyperphosphatemia [+3]

Inactive Indication

Albuminuria [+3]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date12 Sep 2019

Zhuling Jianpi Capsule

Target-

Mechanism-

Active Org.

Jinling Pharmaceutical Co. Ltd. Fuzhou Meifeng Pharmace

Originator Org.

Jinling Pharmaceutical Co., Ltd.

Active Indication

Irritable Bowel Syndrome

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

China

First Approval Date06 Nov 2018

1,785

Clinical Trials associated with Irritable Bowel Syndrome

IRCT20200504047303N1

/ SuspendedNot Applicable

A Double Blind Randomized Clinical Trail: Comparing Lactobacillus plantarum 299v with Placebo in treating irritable bowel syndrome patients

Start Date10 Oct 2635

Sponsor / Collaborator-

NCT06948461

/ Not yet recruitingPhase 2

An Adaptive Basket Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Therapy in Management of Irritable Bowel Syndrome-diarrhea Predominant or Prevention of Recurrent Clostridioides Difficile Infection

The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile infection (rCDI). The main questions it aims to answer are:
* Does ORAL-LYO-FMT reduce IBS symptoms?
* Does it prevent rCDI after treatment?
* What side effects or safety concerns might occur? Researchers will compare ORAL-LYO-FMT to a placebo (a look-alike capsule with no active treatment) to see how well it works.
Participants will:
* Be randomly assigned to take ORAL-LYO-FMT or placebo for up to 7 weeks
* Take capsules three times per week (Monday, Wednesday, Friday)
* Complete health questionnaires and have follow-up visits by phone or in person for up to 6 months The trial also looks at changes in quality of life, mood, and new or ongoing medical conditions over time.

Start Date01 Sep 2025

Sponsor / Collaborator

Pharmaplanter Technologies, Inc.

NCT06760533

/ Not yet recruitingEarly Phase 1IIT

Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.

This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session with single 25 mg oral "high" dose of psilocybin or a single 100 mg dose of niacin (active placebo) and attend 4 post-therapy integration sessions.

Start Date01 Aug 2025

Sponsor / Collaborator

NYU Langone Health

100 Clinical Results associated with Irritable Bowel Syndrome

100 Translational Medicine associated with Irritable Bowel Syndrome

0 Patents (Medical) associated with Irritable Bowel Syndrome

20,555

Literatures (Medical) associated with Irritable Bowel Syndrome

31 Dec 2025·Gut Microbes

A novel framework for assessing causal effect of microbiome on health: long-term antibiotic usage as an instrument

Article

Author: Taba, Nele ; Estonian Biobank Research Team ; Fischer, Krista ; Org, Elin ; Aasmets, Oliver

Assessing causality is undoubtedly one of the key questions in microbiome studies for the upcoming years. Since randomized trials in human subjects are often unethical or difficult to pursue, analytical methods to derive causal effects from observational data deserve attention. As simple covariate adjustment is not likely to account for all potential confounders, the idea of instrumental variable (IV) analysis is worth exploiting. Here we propose a novel framework of antibiotic instrumental variable regression (AB-IVR) for estimating the causal relationships between microbiome and various diseases. We rely on the recent studies showing that antibiotic treatment has a cumulative long-term effect on the microbiome, resulting in individuals with higher antibiotic usage to have a more perturbed microbiome. We apply the AB-IVR method on the Estonian Biobank data and show that the microbiome has a causal role in numerous diseases including migraine, depression and irritable bowel syndrome. We show with a plethora of sensitivity analyses that the identified causal effects are robust and propose ways for further methodological developments.

31 Dec 2025·Blood Pressure

Clinical characterization of blood pressure phenotypes: the BP phenotype score

Article

Author: Aleiban, Hend ; Almalki, Nada A. ; Al Zohaifi, Maisa A. ; Al-Mehisen, Rabah A. ; Al-Mohaissen, Maha A. ; Lee, Terry

BACKGROUNDEvidence has linked blood pressure (BP) phenotypes with certain clinical, psychosocial, and occupational features, and characteristic BP variability.OBJECTIVEWe aimed to evaluate the value of a diagnostic score developed from these characteristics in predicting BP phenotypes, when used in a manner comparable to the application of out-of-office techniques.METHODSAdult patients with no prior diagnosis of hypertension attending their office appointments, were prospectively enrolled. Their clinical, psychosocial, and occupational data were collected. 3-consecutive pre-appointment BP measurements, and BP variability with standing and the 6-minute walk test (6MWT) were obtained. All participants underwent 24-hour BP monitoring which was paired with office BP as the reference standard for BP phenotyping. Two scores were developed from the variables selected using linear regression analysis to differentiate between masked hypertension (MH) and normotension, and sustained hypertension (SH) and white coat hypertension (WCH).RESULTSIn total 212 participants completed the study. Among office-normotensives, a score of 7 (calculated from, variables (points): dyslipidemia (3), irritable bowel syndrome (IBS) (3), orthostatic increase in SBP >5 mmHg (1), SBP increase >10 after 6MWT (1), and BP ≥130/80 after 6MWT (3)) identified MH with 90% sensitivity, 86% specificity, 70% positive predictive value (PPV), and 96% negative predictive value (NPV). Conversely, among office-hypertensives, a score of 6 (male sex (2), no IBS (2), ≥3 metabolic syndrome criteria (3), obesity (3), standing BP ≥140/90 (3), BP ≥140/90 after 6MWT (1)) identified SH with 82% sensitivity, 78% specificity, 90% PPV, and 64% NPV.CONCLUSIONSBP phenotypes correspond to distinct clinical phenotypes and can be predicted with acceptable sensitivity and specificity using BP phenotype scores. This novel approach to BP phenotyping provides an accessible addition, not a replacement, to available out-of-office techniques, particularly useful for screening for MH, and to support office diagnosis of SH when out-of-office measures are unavailable or not tolerated.

31 Dec 2025·Bioengineered

Gut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL)

Article

Author: Dualé, Christian ; Scanzi, Julien ; Durif, Claude ; Brun, Morgane ; Langella, Philippe ; Alric, Monique ; Uriot, Ophélie ; Deschamps, Charlotte ; Kerckhove, Nicolas ; Stéphanie, Blanquet-Diot ; Denis, Sylvain ; Dapoigny, Michel ; Etienne-Mesmin, Lucie ; Fournier, Elora

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, with diarrhea-predominant IBS (IBS-D) as the most frequent subtype. The implication of gut microbiota in the disease's etiology is not fully understood. In vitro gut systems can offer a great alternative to in vivo assays in preclinical studies, but no model reproducing IBS-related dysbiotic microbiota has been developed. Thanks to a large literature review, a new Mucosal ARtifical COLon (M-ARCOL) adapted to IBS-D physicochemical and nutritional conditions was set-up. To validate the model and further exploit its potential in a mechanistic study, in vitro fermentations were performed using bioreactors inoculated with stools from healthy individuals (n = 4) or IBS-D patients (n = 4), when the M-ARCOL was set-up under healthy or IBS-D conditions. Setting IBS-D parameters in M-ARCOL inoculated with IBS-D stools maintained the key microbial features associated to the disease in vivo, validating the new system. In particular, compared to the healthy control, the IBS-D model was characterized by a decreased bacterial diversity, together with a lower abundance of Rikenellaceae and Prevotellaceae, but a higher level of Proteobacteria and Akkermansiaceae. Of interest, applying IBS-D parameters to healthy stools was not sufficient to trigger IBS-D dysbiosis and applying healthy parameters to IBS-D stools was not enough to restore microbial balance. This validated IBS-D colonic model can be used as a robust in vitro platform for studies focusing on gut microbes in the absence of the host, as well as for testing food and microbiota-related interventions aimed at personalized restoration of gut microbiota eubiosis.

745

News (Medical) associated with Irritable Bowel Syndrome

05 May 2025

·www.globenewswire.com

EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025

2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025. Presentation Title: A multicentre randomised double-blind placebo-controlled phase 1b clinical trial evaluating the safety and mechanism of action of EBX-102, an oral pooled intestinal microbiota product, in liver cirrhosis: the IMPuLCE trial Presenter: Professor Ewan Forrest, Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK Session: Cirrhosis I: Cirrhosis & Complications Session date and Time: 09 May 2025, 08:45-09:00 CEST Presentation ID: OS-036 Location: Benhamou Room EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. EBX-102 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including liver cirrhosis and complications thereof, such as hepatic encephalopathy (HE). The content above comes from the network. if any infringement, please contact us to modify.

Microbial therapy

02 May 2025

·www.globenewswire.com

EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025

Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025. Oral Presentation DetailsPresentation Title: A multicentre randomised double-blind placebo-controlled phase 1b clinical trial evaluating the safety and mechanism of action of EBX-102, an oral pooled intestinal microbiota product, in liver cirrhosis: the IMPuLCE trialPresenter: Professor Ewan Forrest, Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UKSession: Cirrhosis I: Cirrhosis & ComplicationsSession date and Time: 09 May 2025, 08:45-09:00 CESTPresentation ID: OS-036Location: Benhamou Room About EnteroBiotixEnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. About EBX-102EBX-102 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including liver cirrhosis and complications thereof, such as hepatic encephalopathy (HE). Media contacts EnteroBiotixDr James McIlroy, CEOinfo@enterobiotix.com ICR HealthcareNamrata Taak, Kris Lamenterobiotix@ICRHealthcare.com

Phase 1Microbial therapy

28 Apr 2025

·www.globenewswire.com

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA. Late-Breaker Presentation DetailsPresentation Title: A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal microbiota product, in patients with irritable bowel syndrome with constipation; the TrIuMPH trialPresenter: Professor Anthony HobsonAbstract Number: 987bEmbargoed Until: 06 May 2025, 12:01 am PDTSession Title: DDW Clinical Science Late-Breaking Abstract PlenarySession date and Time: 06 May 2025, 08:15-08:30 am PDTLocation: Room 6A (SDCC) About EnteroBiotixEnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. About EBX-102-02 EBX-102-02 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102-02 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including irritable bowel syndrome (IBS). Media contacts EnteroBiotixDr James McIlroy, CEOinfo@enterobiotix.com ICR HealthcareNamrata Taak, Kris Lamenterobiotix@ICRHealthcare.com

Phase 2Microbial therapy

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Irritable Bowel Syndrome

Basic Info

Related

Analysis